Education
About Us
Working with TipRanks
Follow Us
PTC Therapeutics (PTCT)
NASDAQ:PTCT
PTCT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$30.41 - $58.38
Previous CloseN/A
Volume146.45K
Average Volume (3M)1.12M
Market Cap
$3.60B
Enterprise Value$2.22B
Total Cash (Recent Filing)$2.03B
Total Debt (Recent Filing)$389.62M
Price to Earnings (P/E)6.5
Beta1.30
Next Earnings
Oct 23, 2025EPS Estimate
-1.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.83
Shares Outstanding79,438,095
10 Day Avg. Volume1,573,937
30 Day Avg. Volume1,117,081
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)-3.16
Price to Sales (P/S)4.30
P/FCF Ratio-30.38
Enterprise Value/Market Cap0.62
Enterprise Value/Revenue1.25
Enterprise Value/Gross Profit1.30
Enterprise Value/Ebitda2.66
Forecast
1Y Price Target
$67.79Price Target Upside40.73% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering16
Bulls Say, Bears Say
Bulls Say
Financial PerformanceTotal net product revenue and royalty revenue came in ahead of consensus expectations.
Product LaunchThe approval of Sephience for PKU has generated broad community enthusiasm, with new patient start forms beginning immediately, suggesting strong market interest.
Strategic DecisionsThe purchase of the percentage-based global sales obligation related to Sephience from former Censa shareholders is seen as a net positive, reflecting PTC’s confidence.
Bears Say
Product Approval UncertaintyThere is cautious optimism regarding the US PDUFA for vatiquinone, with a slightly better than 50/50 possibility of approval, indicating some uncertainty in the pipeline.
Product CompetitionA decline in Emflaza revenue was reported for the quarter due to generics market erosion.
Regulatory ChallengesThe review of vatiquinone for Friedreich's ataxia is going a bit more slowly than expected as PTCT said they had their late-cycle meeting and have not yet started labeling discussions with the FDA.
PTC Therapeutics News
PTCT FAQ
What was PTC Therapeutics’s price range in the past 12 months?
PTC Therapeutics lowest stock price was $30.41 and its highest was $58.38 in the past 12 months.
What is PTC Therapeutics’s market cap?
PTC Therapeutics’s market cap is $3.60B.
When is PTC Therapeutics’s upcoming earnings report date?
PTC Therapeutics’s upcoming earnings report date is Oct 23, 2025 which is in 70 days.
How were PTC Therapeutics’s earnings last quarter?
PTC Therapeutics released its earnings results on Aug 07, 2025. The company reported -$0.83 earnings per share for the quarter, beating the consensus estimate of -$1.021 by $0.191.
Is PTC Therapeutics overvalued?
According to Wall Street analysts PTC Therapeutics’s price is currently Undervalued.
Does PTC Therapeutics pay dividends?
PTC Therapeutics does not currently pay dividends.
What is PTC Therapeutics’s EPS estimate?
PTC Therapeutics’s EPS estimate is -1.03.
How many shares outstanding does PTC Therapeutics have?
PTC Therapeutics has 79,438,095 shares outstanding.
What happened to PTC Therapeutics’s price movement after its last earnings report?
PTC Therapeutics reported an EPS of -$0.83 in its last earnings report, beating expectations of -$1.021. Following the earnings report the stock price went down -9.889%.
Which hedge fund is a major shareholder of PTC Therapeutics?
Currently, no hedge funds are holding shares in PTCT
PTC Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$67.79 (40.73% Upside)
$67.79 (40.73% Upside)
Blogger Sentiment
Bullish
PTCT Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 762.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $680.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.2%
Last 30 Days ▲ 10.5%
Last 30 Days ▲ 10.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
44.58%
12-Months-Change
Fundamentals
Return on Equity
33.08%
Trailing 12-Months
Asset Growth
37.46%
Trailing 12-Months
Company Description
PTC Therapeutics
PTC Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines to treat rare diseases and other serious conditions. The company operates primarily in the biotechnology sector, targeting genetic disorders with a core emphasis on translational medicine. PTC Therapeutics is known for its lead products, including Translarna™ (ataluren), which is designed to treat certain types of Duchenne muscular dystrophy, and Emflaza™ (deflazacort), a corticosteroid for the treatment of Duchenne muscular dystrophy in patients 5 years and older.
PTCT Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong quarter for PTC Therapeutics, highlighted by the approval and launch of Sephience, which is expected to drive significant future revenue. The company maintains a solid financial position, supporting their strategic initiatives. However, challenges such as the Emflaza market erosion and uncertainty surrounding the vatiquinone NDA remain. Overall, the positive developments, particularly the Sephience launch, outweigh the negatives.View all PTCT earnings summariesPTCT Stock 12 Month Forecast
Average Price Target
$67.79
▲(40.73% Upside)
Technical Analysis
Ultragenyx Pharmaceutical
―
Rhythm Pharmaceuticals
―
Avidity Biosciences
―
Arcellx Inc
―
Ownership Overview
1.31% Insiders
25.72% Mutual Funds
0.90% Other Institutional Investors
52.39% Public Companies and
Individual Investors